Nexalin Technology (NXL) Expected to Announce Earnings on Friday

Nexalin Technology (NASDAQ:NXL) is expected to be announcing its results before the market opens on Friday, March 13th. Analysts expect the company to announce earnings of ($0.12) per share and revenue of $0.08 million for the quarter.

Nexalin Technology Trading Down 1.2%

Shares of NASDAQ:NXL opened at $0.44 on Friday. The stock has a fifty day simple moving average of $0.57 and a two-hundred day simple moving average of $0.89. Nexalin Technology has a 12-month low of $0.37 and a 12-month high of $2.57. The stock has a market capitalization of $8.14 million, a price-to-earnings ratio of -0.66 and a beta of 4.05.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on NXL. Wall Street Zen lowered Nexalin Technology from a “hold” rating to a “sell” rating in a research report on Saturday, November 22nd. Weiss Ratings restated a “sell (d-)” rating on shares of Nexalin Technology in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Nexalin Technology currently has a consensus rating of “Hold” and a consensus price target of $5.00.

Institutional Investors Weigh In On Nexalin Technology

Several large investors have recently bought and sold shares of the business. PEAK6 LLC purchased a new stake in shares of Nexalin Technology during the 4th quarter valued at about $266,000. Renaissance Technologies LLC lifted its position in Nexalin Technology by 119.2% during the fourth quarter. Renaissance Technologies LLC now owns 122,100 shares of the company’s stock valued at $68,000 after purchasing an additional 66,400 shares during the period. Geode Capital Management LLC boosted its holdings in Nexalin Technology by 23.4% in the fourth quarter. Geode Capital Management LLC now owns 150,274 shares of the company’s stock worth $84,000 after purchasing an additional 28,454 shares during the last quarter. Finally, Susquehanna International Group LLP bought a new stake in Nexalin Technology in the 3rd quarter worth approximately $57,000. 0.65% of the stock is currently owned by institutional investors.

Nexalin Technology Company Profile

Nexalin Technology, Inc is a U.S.-based medical device company specializing in noninvasive neuromodulation therapies for mental health conditions. The company develops and markets the Nexalin® medical device platform, which delivers proprietary alternating current waveforms to targeted areas of the brain through forehead-mounted electrodes. Its technology is designed to modulate neural activity without pharmaceuticals, positioning the company within the growing field of digital therapeutics and neurostimulation.

The Nexalin device has received U.S.